DWTX_OUT_1 [2025-04-15 15:10:11 -0400] 3802 Bytes | 964 tokens | Cum: 964 tkns (12.05% of 8k)
==========================================================================

We need a winner today and it's already 3:10:09 PM on Tue Apr 15, 2025 -0400 ... So let's find out if Dogwood Therapeutics (DWTX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 4.0500 up from 3.0000. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Dogwood Therapeutics (DWTX)
IPO: 2020-12-17 (4 Years Ago)
Market Cap: $6,746,282
Shares Outstanding: 1,910,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Here’s a list of headlines for Dogwood Therapeutics:

Apr-11-25 09:15AM - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Apr-03-25 09:00AM - Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Mar-31-25 03:45PM - Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar-18-25 08:45AM - Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain
Mar-14-25 12:15PM - Biotech Alert: Searches spiking for these stocks today
Mar-13-25 09:00AM - Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Mar-12-25 08:30AM - Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
Jan-21-25 09:15AM - Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-09T17:00:00Z - Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Dogwood Therapeutics (DWTX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

DWTX_OUT_3 [2025-04-15 15:10:12 -0400] 915 Bytes | 262 tokens | Cum: 1228 tkns (15.35% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-15T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Apt...
A2 - 2025-04-11T13:15:43Z - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance...
A3 - 2025-04-11T13:36:39Z - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance...
A4 - 2025-04-11T13:15:43Z - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance...
A5 - 2025-04-11T13:26:16Z - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

DWTX_OUT_5 [2025-04-15 15:10:13 -0400] 1181 Bytes | 349 tokens | Cum: 1579 tkns (19.74% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Aptorum Gr (NASDAQ:APM)**Date: 2025-04-15Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44820863/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Mural Oncology MURA stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million. Skye Bioscience SKYE stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million. Dogwood Therapeutics DWTX stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million. Phio Pharma PHIO shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million. Verve Therapeutics VERV shares increased

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_7 [2025-04-15 15:10:14 -0400] 1181 Bytes | 358 tokens | Cum: 1939 tkns (24.24% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): by 24.51% to $5.13. The company's market cap stands at $455.5 million. Aptorum Gr APM stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million. Losers Spruce Biosciences SPRB stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today. MetaVia MTVA stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million. MSP Recovery MSPR shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million. Impact BioMedical IBO shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million. Geovax Labs GOVX shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million. Sharps Technology STSS stock fell 19.3% to $0.03. See Also: www.benzinga.com/money/best-h

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_9 [2025-04-15 15:10:15 -0400] 1041 Bytes | 348 tokens | Cum: 2289 tkns (28.61% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ealthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

APMAptorum Group Ltd$0.910011.7%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum3.77Price TrendShortMediumLongOverviewDWTXDogwood Therapeutics Inc$4.0334.3%GOVXGeovax Labs Inc$0.9021-15.7%IBOImpact BioMedical Inc$0.3809-20.7%MSPRMSP Recovery Inc$2.23-21.0%MTVAMetaVia Inc$1.18-35.9%MURAMural Oncology PLC$2.56149.0%PHIOPhio Pharmaceuticals Corp$2.7625.4%SKYESkye Bioscience Inc$1.8138.5%SPRBSpruce Biosciences Inc$0.1410-55.1%STSSSharps Technology Inc$0.0351-17.4%VERVVerve Therapeutics Inc$5.1424.9%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_11 [2025-04-15 15:10:17 -0400] 1102 Bytes | 278 tokens | Cum: 2569 tkns (32.11% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing e...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Dogwood Therapeutics, Inc. (the Company) issued a press release announcing the results of operations for the fourth quarter and full year ended December 31, 2024. A copy of the press release is included...

S5 - 2025-03-14 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 12, 2025, Dogwood Therapeutics, Inc. (the Company ) entered into a stock purchase agreement (the Purchase Agrmt ) with certain non-affiliated institutional investors (the Purchasers ) pursuant to which the Compa...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DWTX_OUT_13 [2025-04-15 15:10:18 -0400] 1181 Bytes | 239 tokens | Cum: 2810 tkns (35.12% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties, including those set forth under Cautionary Statement About Forward-Looking Statements. Actual results and experience could differ materially from the anticipated results and other expectations expressed in our forward-looking statements as a result of a number of factors, including but not limited to those discussed in this Item and in Part I, Item 1A. Risk Factors. Actual results and the timing of events could differ materially from those di

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_15 [2025-04-15 15:10:18 -0400] 1181 Bytes | 273 tokens | Cum: 3085 tkns (38.56% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): scussed in our forward-looking statements as a result of many factors, including those set forth under Risk Factors and elsewhere in this Annual Report on Form 10-K.

Summary Overview

We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. Our pipeline is focused on two separate pillars: Na v 1.7 modulation to treat chronic and acute pain disorders and combination antiviral therapies targeting reactivated herpes virus mediated illnesses. The proprietary non-opioid Na V 1.7 analgesic program is centered on our lead development candidate Halneuron , which is a voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals an

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_17 [2025-04-15 15:10:21 -0400] 1181 Bytes | 291 tokens | Cum: 3378 tkns (42.23% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): d the anti-inflammatory agent celecoxib for the treatment of FM and LC.

Na v 1.7 Non-Opioid Analgesic Program

Our lead product candidate, Halneuron , is in late-stage clinical development for the treatment of CINP. The active pharmaceutical ingredient is highly purified TTX, a potent sodium channel modulator found in puffer fish and several other marine animals. Halneuron works as an analgesic by modulating the activity of Na v 1.7, a key sodium channel involved in pain signal transmission. By reducing the activity of the Na v 1.7 channel, Halneuron has the potential to reduce pain associated with conditions involving neuropathic pain.

In the first quarter of 2025, we commenced a HALT-CINP-203 clinical trial in the United States. HALT-CINP-203 is a double-blind, placebo controlled clinical trial to access the efficacy and safety of Halneuron in 200 patients with moderate to severe n

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_19 [2025-04-15 15:10:22 -0400] 1181 Bytes | 280 tokens | Cum: 3660 tkns (45.75% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): europathic pain caused by previous platinum and/or taxane chemotherapy. The primary efficacy endpoint is the change from baseline at week 4 in the weekly average of daily 24-hour recall pain intensity scores, comparing Halneuron to the placebo. The secondary endpoints are patient global impression of change, PROMIS regarding fatigue, PROMIS related to sleep, PROMIS-29, pain interference, hospital anxiety and depression scale and neuropathic pain symptom inventory. We expect to release interim data from HALF-CINP-203 in the second half of 2025.

Antiviral Program

We plan to continue development of IMC-1 and IMC-2 which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib. IMC-1 is a novel combination of famciclovir and celecoxib intended to synergistically suppress herpesvirus activation and replication, w

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_21 [2025-04-15 15:10:22 -0400] 1181 Bytes | 280 tokens | Cum: 3942 tkns (49.28% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ith the end goal of reducing a patients viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that like IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4).

Share Exchange Agreement

On October 7, 2024, the Company, entered into the Exchange Agreement with Sealbond, pursuant to which the Company acquired 100% of the issued and outstanding common shares of Pharmagesic and the parent company of Wex Pharmaceuticals, Inc. in the Combination. Prior to the Combination, Pharmagesic was a

wholly-owned subsidiary of Sealbond and an indirect wholly-owned subsidiary of CKLS, a listed entity on the Main Board of the Hong Kong Stock Exchange.

Loan Agreement

On October 7, 2024, in connection with the Exchange Agreement, the Company entered into a Loan

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_23 [2025-04-15 15:10:23 -0400] 790 Bytes | 209 tokens | Cum: 4153 tkns (51.91% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): Agreement (the Loan Agreement) with Conjoint Inc., a Delaware corporation (Lender). Pursuant to the Loan Agreement, Lender agreed to make a loan to the Company in the aggregate principal amount of $19,500,000, of which (i) $16,500,000 was disbursed on October 7, 2024 and (ii) $3,000,000 was disbursed on February 18, 2025. Prior to the Debt Exchange and Cancellation Transaction described below, the Loan Agreement bore interest at the Secured Overnight Financing Rate (SOFR). The Loan Agreement was pay...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

DWTX_OUT_25 [2025-04-15 15:10:30 -0400] 5962 Bytes | 1420 tokens | Cum: 5575 tkns (69.69% of 8k)
==========================================================================

This is our set of metrics for Dogwood Therapeutics.
Please analyze the numbers.

+--------------------+----------------------+------------------------+------------------------+
| Volume: 19,238,688 | Perf Month: -34.62% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+----------------------+------------------------+------------------------+
| Avg Volume: 3.57M | Perf Quarter: 78.54% | Short Float: 6.66% | ROE: -200.48% |
+--------------------+----------------------+------------------------+------------------------+
| Rel Volume: 6.40 | Index: - | Short Ratio: 0.03 | ROI: -16.12% |
+--------------------+----------------------+------------------------+------------------------+
| RSI (14): 42.93 | Market Cap: 7.60M | Short Interest: 0.10M | Sales Surprise: - |
+--------------------+----------------------+------------------------+------------------------+
| ATR (14): 1.08 | Shs Outstand: 1.91M | Beta: 2.17 | EPS Surprise: -344.52% |
+--------------------+----------------------+------------------------+------------------------+
| SMA20: -16.58% | Shs Float: 1.56M | Sales Q/Q: - | P/E: - |
+--------------------+----------------------+------------------------+------------------------+
| SMA50: -35.20% | Inst Own: 1.61% | Sales past 5Y: 0.00% | Earnings: Mar 14 BMO |
+--------------------+----------------------+------------------------+------------------------+
| SMA200: -20.07% | Insider Own: 18.63% | Employees: 12 | |
+--------------------+----------------------+------------------------+------------------------+
| Perf Week: 10.29% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+----------------------+------------------------+------------------------+

The next section covers any insider trading by Dogwood Therapeutics officers or majority shareholders (if available).

No transactions recorded.

Inside Trans: Dogwood Therapeutics, Inc. (DWTX) by CK Life Sciences Intl (Holdings) Inc (Unknown Title) on 2025-03-12
- Series A-1 Preferred Stock: 284.2638 shares at $7.01 (I) Footnote: On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the "Loan Agreement"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.05
Average Volume: 1038667.09
30-Day High: 6.83
30-Day Low: 2.94
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Dogwood Therapeutics (DWTX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Dogwood Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because DWTX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for DWTX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, DWTX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect DWTX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Dogwood Therapeutics.

11) ETHICAL_RATING[]
Rate Dogwood Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Dogwood Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

DWTX_IN_27 [2025-04-15 15:10:31 -0400] 126 Bytes | 29 tokens | Cum: 5802 tkns (72.52% of 8k)
==========================================================================

====================================
[2025-04-15 15:10:31] # Analysis Completed
Elapsed Time: 21.68 seconds